Study supports use of androgen receptor inhibitors in older men with nmCRPCJuly 26th 2021
Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.
MRI-guided screening limits prostate cancer overdiagnosisJuly 16th 2021
Prostate cancer screening with MRI-guided biopsy reduced the detection of clinically insignificant prostate cancer versus use of standard biopsy alone, while also demonstrating noninferiority for detecting clinically significant disease.
Ga-68 PSMA PET shows high specificity in predicting lymph node invasion in prostate cancerJuly 12th 2021
With supporting data from larger series, using Ga-68 PSMA PET as a lymph node invasion prediction tool instead of nomograms could avoid unnecessary lymphadenectomies during radical prostatectomy,” said Yakup Kordan, MD.
Neoadjuvant stereotactic ablative radiation shows promise for invasive renal cell carcinomaJuly 2nd 2021
Neoadjuvant stereotactic ablative radiation followed by radical nephrectomy and thrombectomy was safe and showed signs of positive clinical activity in patients with renal cell carcinoma and inferior vena cava tumor thrombus.